Intercept Pharmaceuticals to Present at Deutsche Bank Healthcare Conference
NEW YORK, May 23, 2013
NEW YORK, May 23, 2013 /PRNewswire/ --Intercept Pharmaceuticals, Inc.
(Nasdaq: ICPT) (Intercept), a clinical stage biopharmaceutical company focused
on the development and commercialization of novel bile acid therapeutics to
treat chronic liver diseases, such as primary biliary cirrhosis, today
announced that Mark Pruzanski, MD, President and Chief Executive Officer, will
present at the Deutsche Bank Securities 38th Annual Health Care Conference in
Boston on Wednesday, May 29, 2013 at 4:10 p.m. ET.
Intercept is a biopharmaceutical company focused on the development and
commercialization of novel therapeutics to treat orphan and more prevalent
liver diseases, such as primary biliary cirrhosis, utilizing its expertise in
bile acid chemistry. The company's lead product candidate, obeticholic acid
(OCA) is a bile acid analog and first-in-class agonist of the farnesoid X
receptor (FXR). OCA is initially being developed for the second line treatment
of primary biliary cirrhosis (PBC) in patients with an inadequate response to,
or who are unable to tolerate, ursodiol, the only approved therapy for this
indication. OCA has received orphan drug designation in both the United States
and Europe for the treatment of PBC. Intercept owns worldwide rights to OCA
outside of Japan and China, where it has out-licensed the product candidate to
DSP. For more information about Intercept, please visit the Company's website
SOURCE Intercept Pharmaceuticals, Inc.
Contact: Mark Pruzanski, M.D., or Barbara Duncan, both of Intercept
Press spacebar to pause and continue. Press esc to stop.